Cargando…

A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease

A randomized thorough QT study was conducted to assess the effects of apomorphine sublingual film (SL‐APO) on corrected QT interval (QTc) and other cardiac conduction parameters in patients with Parkinson's disease (PD) and “OFF” episodes. Patients were titrated to an SL‐APO dose that resulted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stocchi, Fabrizio, Peckham, Elizabeth L., De Pandis, Maria Francesca, Sciarappa, Ken, Kleiman, Robert, Agbo, Felix, Olanow, C. Warren, Blum, David, Navia, Bradford
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541463/ https://www.ncbi.nlm.nih.gov/pubmed/35899977 http://dx.doi.org/10.1002/cpdd.1147

Ejemplares similares

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
por: Agbo, Felix, et al.
Publicado: (2021)

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
por: Agbo, Felix, et al.
Publicado: (2021)

Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?
por: Hauser, Robert A., et al.
Publicado: (2023)

Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson’s Disease
por: Thach, Andrew, et al.
Publicado: (2021)

Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study
por: Kassubek, Jan, et al.
Publicado: (2023)

A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects
por: Adar, Liat, et al.
Publicado: (2015)

“Thorough QT/QTc in a Dish”: Can Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Predict Thorough QT Outcomes?
por: Vargas, Hugo M.
Publicado: (2019)

Apomorphine in Parkinson's Disease—The Questions Raised
por: Dhamija, Rajinder K., et al.
Publicado: (2020)

Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
por: Hagell, Peter, et al.
Publicado: (2020)

Apomorphine
Publicado: (1900)

Apomorphine
Publicado: (1888)

Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects
por: Ring, Arne, et al.
Publicado: (2013)

No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
por: Demmel, Valentin, et al.
Publicado: (2018)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Task Specific Tremor in Parkinson’s Disease Responds to Apomorphine
por: Ondo, William G., et al.
Publicado: (2023)

Apomorphine Monotherapy for Parkinson’s Disease: A Neglected Option?
por: Desjardins, Clément, et al.
Publicado: (2023)

Utility of tolcapone in fluctuating Parkinson’s disease
por: Stocchi, Fabrizio, et al.
Publicado: (2006)

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
por: Carlson, Glenn F., et al.
Publicado: (2011)

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease
por: Isaacson, Stuart, et al.
Publicado: (2016)

Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations
por: Carbone, Federico, et al.
Publicado: (2019)

Investigation of apomorphine during sleep in Parkinson’s: Improvement in UPDRS Scores
por: Pieroni, Miguel A.
Publicado: (2019)

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
por: Ring, Arne, et al.
Publicado: (2013)

Apomorphine effects on the hippocampus
por: Arroyo-García, Luis Enrique, et al.
Publicado: (2018)

On the Anæsthetic Action of Apomorphine
Publicado: (1885)

Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study
por: Ilic, Katarina, et al.
Publicado: (2020)

Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease
por: Passamonti, Luca, et al.
Publicado: (2013)

Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
por: Borkar, Nrupa, et al.
Publicado: (2018)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016)

The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study
por: Palmisano, Maria, et al.
Publicado: (2016)

Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study
por: Shen, Zancong, et al.
Publicado: (2016)

Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals
por: Darpo, Borje, et al.
Publicado: (2017)

Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants
por: Lissy, Michael, et al.
Publicado: (2020)

How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
por: Meyer, Claudia, et al.
Publicado: (2022)

Some Observations on the Use of Apomorphine
por: Horsley, J. S.
Publicado: (1912)

Is Apomorphine a Safe Emetic?
por: Brown, John
Publicado: (1889)

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
por: Gaire, Suman, et al.
Publicado: (2021)

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
por: Werner, Milton H., et al.
Publicado: (2021)

Thoroughness
por: Dotterer, L. P.
Publicado: (1885)

Cannot write session to /tmp/vufind_sessions/sess_jlpg70uaed4p320l2dqdoe7den